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Adverse effectNonconvulsive status epilepticus (NCSE) can be triggered bymetabolic disturbances and drugs in adults without
previous epilepsy.Wepresent the case of a 51-year-oldwomanwithout previous history of epilepsy and recently
diagnosed with inﬁltrating lobular breast carcinoma. Following the administration of paclitaxel–cremophor, she
presented a striking disinhibited behavior with episodic spatial disorientation, emotional indifference, and irrita-
bility. Urgent EEG was consistent with NCSE. Clinical improvement and resolution of EEG abnormalities were
observed following the administration of intravenous levetiracetam and lacosamide. Other causes of NCSE
were ruled out, and antiepileptic drugs were slowly tapered off without new episodes of abnormal behavior
after three months of follow-up. We have reported the ﬁrst case of NCSE secondary to paclitaxel–cremophor.
Neurologists and oncologists should consider NCSE as an unusual complication of treatment with paclitaxel–
cremophor in patients without a history of epilepsy.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND 4.0 license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Nonconvulsive status epilepticus (NCSE) can be triggered by meta-
bolic disturbances and drugs in adults without previous epilepsy. With
patients with cancer in particular, some chemotherapeutic agents
have been associated with encephalopathy and seizures, complicating
the diagnostic approach in the context of behavioral changes.We report
a case of NCSE closely related to the administration of paclitaxel–
cremophor and conduct a review of the literature to explore this
relationship.2. Case report
A 51-year-old woman presented to our emergency department,
accompanied by relatives worried about her strange behavior. She had
no medical history other than breast cancer diagnosed at the pN1a
stage (HER2 negative), which was successfully treated with local radio-
therapy and chemotherapy during the last year. She took no regular
medication other than previous treatments for cancer, which included
four cycles of cytarabine and etoposide without signiﬁcant adverse
effects. However, paclitaxel formulated with the micelle-forming vehi-
cle cremophor was started eight days before the ﬁrst symptoms. Sinceposition on issues involved in
t with those guidelines.
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.
. This is an open access article underthen, the family reported episodes of disorientation, difﬁculty recogniz-
ing close persons, and striking disinhibited behavior. The patient
performed compulsive shopping, spending her savings; showed socially
inappropriate behavior, including inappropriate laughing on several
occasions; and was nearly struck by a vehicle because of her careless
attitude. The day before being admitted to the emergency department,
the patient attended her follow-up consultation in oncology. Relatives
were informed that she started to undress in the waiting room and
demanded to speak to her doctor immediately. The patient behaved
aggressively and left the hospital without being evaluated. When
asked about these latest incidents, the patient afﬁrmed remembering
them, considering them very amusing. Her family convinced her to
seek medical attention.
During the examination at the emergency room, she did not seem
concerned about the situation. Physical examination was uninforma-
tive. She was cooperative and oriented, her language was ﬂuent and
appropriate, and she was able to respond to simple commands. The
rest of the neurological examination was normal. Routine laboratory
tests ruled out infectious or metabolic disorders, and computed tomog-
raphy of the brain was unremarkable. An urgent electroencephalogram
(EEG) was performed (Fig. 1A) showing continuous generalized sharp-
wave activity consistent with the diagnosis of nonconvulsive status
epilepticus (NCSE) alternating with occasional bilateral-prominent
frontal activity (Fig. 1B).
No changes were observed after the administration of 4 mg of intra-
venous diazepam. Afterwards, 1000 mg of levetiracetam was adminis-
tered with a marked improvement of the electroencephalographic
trace but without complete resolution of EEG abnormalities. Finally,
although clinical assessment was hindered by patient sleepiness,the CC BY-NC-ND 4.0 license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Urgent EEG after admittance. (A) Urgent EEG showing the existence of bilateral continuous sharp-wave frontal activity consistent with nonconvulsive status epilepticus. (B) The
same EEG showing intermittent burst of sharp waves of frontal-predominant distribution (black arrows). Horizontal bars = 1 s. Sensibility: 50 μV (1 mm vertical).
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the administration of 200 mg of intravenous lacosamide. The patient
was admitted to the neurology ward, and a complete study of de novo
status epilepticus in the patient without epilepsy was performed.
Laboratory data did not show any abnormalities. Antibodies directed
against surface and intraneuronal antigenswere negative, andmagnetic
resonance imaging, including DWI sequence and contrast administra-
tion, was unremarkable. A nontraumatic lumbar puncture was per-
formed within the ﬁrst 24 h of admission, and spinal ﬂuid did not
show any abnormality. Neither tumoral cells nor oligoclonal bands
were detected. Forty-eight hours later, a new EEG was performed,
showing complete normalization of the trace with the exception of
occasional left temporal bursts of low amplitude sharp waves (Fig. 2).
The patient declared feeling very ashamed of her acts from the past
few days, being able to remember the majority of them. Serial EEG was
normal, and treatmentwith lacosamidewas ﬁrst discontinuedwhile le-
vetiracetamwas slowly tapered off, without new episodes of abnormal
behavior after three months of follow-up. Treatment with paclitaxel
was discontinued.
A total of three cases corresponding to seizures (GTCS in all cases)
and 11 to acute encephalopathy secondary to paclitaxel administrationFig. 2. Control EEG performed 48 h after the start of treatment. Control EEG, 48-hours posttreatm
transient sharp-wave activity on the left hemisphere (dotted box). Horizontal bars = 1 s, Vertwere identiﬁed in our review. No previous cases of NCSE secondary to
paclitaxel were identiﬁed.
3. Discussion
We have described, to our knowledge, the ﬁrst case of nonconvulsive
status epilepticus secondary to the administration of paclitaxel and
cremophor (for further details, see Supplementary information). Pacli-
taxel is a chemotherapeutic agent commonly prescribed to treat a wide
variety of solid tumors in addition to breast cancer. It promotes the as-
sembly of microtubules from tubulin dimers and stabilizes microtubules
by preventing depolymerization. It is known to cause peripheral neuro-
toxicity, but central nervous system toxicity has been rarely described,
in contrast to other chemotherapeutic agents such as ifosfamide, proba-
bly because of its difﬁculties crossing the blood–brain barrier. However,
it has been reported as a cause of GTCS and acute encephalopathy [1].
Moreover, cremophor, a micelle-forming agent associated with paclitax-
el, is considered a neurotoxic agent. In fact, it has been associated with
GTCS, EEG burst suppression patterns, and axonal swelling in rats [2].
We used the Naranjo Adverse Drug Reaction Probability Scale to deter-
mine the probability of an association between paclitaxel–cremophorent start, showing complete normalization of the trace with the exception of low-voltage
ical: 100 μV/cm.
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association was probable.
Nonconvulsive status epilepticus can be divided into generalized or
focal according to clinical and EEG features [4]. Even though absence
status (AE) is associated with idiopathic general epilepsies, it may also
present “de novo” in adults without epilepsy, and differentiating from
frontal focal NCSE (FNCSE) can be challenging, if not impossible [4].
De novo late AE may present as in the described case, in a middle-
aged adult with abnormal behavior, slight cognitive disturbances, and
a preserved level of consciousness. Moreover, FNCSE is a largely unrec-
ognized form of status epilepticus often resistant to antiepileptic thera-
py. In the described case, three antiepileptic drugs were required for
seizure termination on EEG monitoring. Patients may show striking
frontal semiology and are otherwise able to perform normal-living
activities. Interestingly, O'Connor reported a case of a delayed GTCS
related to paclitaxel treatment with frontal-predominant spike–wave
activity on EEG. However, this patient did not show clinical features
consistent with NCSE [2].
Both neurologists and oncologists should be aware of this unusual
complication of treatment with paclitaxel and cremophor in patients
with no history of epilepsy.Acknowledgments
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